Objective: To explore the effect of general comprehensive treatment program on blood sugar control and insulin dosage in patients with type 2 diabetes. Methods: 86 patients with type 2 diabetes admitted from January 2022 to December 2023 were selected and randomly divided into a control group of 43 cases (conventional hypoglycemic regimen) and an observation group of 43 cases (general comprehensive intervention). The glycated hemoglobin (HbA1c), fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPG), insulin dosage, and occurrence of adverse reactions were compared between the two groups of patients after 3 months of treatment. Results: Before intervention, the HbA1c of the two groups of patients (control group was 8.42 ± 1.35%, observation group was 8.38 ± 1.41%), FPG (control group was 9.25 ± 1.72 mmol/L, observation group was 9.18 ± 1.68 mmol/L) difference was not statistically significant (p > 0.05); after intervention, the HbA1c of the observation group dropped to 7.02 ± 0.93%, which was significantly lower than the 7.89 ± 1.12% of the control group (p < 0.05). FPG (6.85 ± 1.02 mmol/L) and 2hPG (9.06 ± 1.34 mmol/L) were lower than those of the control group (7.94 ± 1.25). mmol/L, 10.87 ± 1.59 mmol/L) decreased more significantly (p < 0.05). The average daily insulin consumption of the observation group was 32.15 ± 6.84 U, which was less than 41.27 ± 7.53 U of the control group (p < 0.05). The total effective rate of the observation group was higher than that of the control group, and the adverse reactions were lower than that of the control group (p < 0.05). Conclusion: A comprehensive treatment program can effectively improve blood sugar control, reduce insulin dependence, and reduce the risk of hypoglycemia in patients with type 2 diabetes.